•  
  •  
  •  
  •  

2025-09-28 17:20:04

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark

Keywords Selected:  NatcoPharma

Research

  • Natco Pharma - Natco and Teva launch Revlimid in the US - ICICI Securities

Stock Report

  • NATCO Pharma Ltd updates on acquisition of Adcock Ingram
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur
  • USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
  • NATCO Pharma Ltd - Legal Update regarding Risdiplam
  • Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic
  • NATCO Pharma Canada Inc. announces US$ 8 million investment in eGenesis, Inc.
  • Natco Pharma Ltd announces submission of Abbreviated New Drug Application
  • NATCO Pharma Ltd updates on complaint by Fresenius
  • NATCO Pharma Ltd receives warning letter from USFDA for facility in Kothur, Telangana
  • NATCO Pharma Limited invests around US$ 2 million in Cellogen Therapeutics Private Limited
  • Natco Pharma Ltd and Breckenridge dismissed from antitrust lawsuit
  • Operations disrupted at NATCO Pharma's Manali, Chennai factory
  • Natco Pharma Ltd posts consolidated Q2FY24 PAT of Rs. 369 crores
  • NATCO Pharma announces successful completion of USFDA inspection
  • Natco Pharma Ltd receives 8 observations from USFDA for Pharma Division at Kothur
  • NATCO Pharma Ltd included as defendant in antitrust lawsuit in the US
  • Natco Pharma's consolidated PAT in Q1FY24 jumps to Rs. 420.3 crores
  • NATCO files generic Erdafitinib Tablets in USA
  • NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine for the US market
  • Natco Pharma receives EIR from USFDA for Vizag facility
  • Natco Pharma Ltd consolidated Q4 FY2023 PAT jumps to Rs. 275.8 crores
  • NATCO Pharma Limited to form subsidiary in Indonesia
  • NATCO launches additional strengths for the Generic Version of Revlimid® in USA

Latest Post

  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024